TickerFacts.

Recursion Pharmaceuticals, Inc. (RXRX): Shareholders' Equity

Annual figures by period end, from SEC filings.

$1.13B
As of 2025-12-31
$915.00M
As of 2026-06-30
+32.5%
3-year compound annual growth
2019-12-31: -$124.27M2020-12-31: -$206.29M2021-12-31: $542.94M2022-12-31: $485.81M2023-12-31: $463.44M2024-12-31: $1.03B2025-12-31: $1.13B$1.13B
2019-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$1.13B+9.3%2026-02-25, Balance as of period end
2024-12-31$1.03B+123.3%2026-02-25, Balance as of period end
2023-12-31$463.44M-4.6%2026-02-25, Balance as of period end
2022-12-31$485.81M-10.5%2025-02-28, Balance as of period end
2021-12-31$542.94Mn/m2024-02-29, Balance as of period end
2020-12-31-$206.29Mn/m2023-02-27, Balance as of period end
2019-12-31-$124.27Mn/a2022-03-23, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Recursion Pharmaceuticals, Inc. (RXRX)2025-12-31$1.13B+9.3%
Autolus Therapeutics plc (AUTL)2025-12-31$178.13M-58.3%
Compugen Ltd (CGEN)2025-12-31$102.73M+87.1%
Black Diamond Therapeutics, Inc. (BDTX)2025-12-31$112.21M+34.7%
Vir Biotechnology, Inc. (VIR)2025-12-31$765.28M-33.5%
MeiraGTx Holdings plc (MGTX)2025-12-31-$5.79Mn/m
4D Molecular Therapeutics, Inc. (FDMT)2025-12-31$505.66M-1.0%
Champions Oncology, Inc. (CSBR)2026-04-30$3.94M+4.4%
Sutro Biopharma, Inc. (STRO)2025-12-31-$132.45Mn/m

Compare RXRX, AUTL, CGEN, BDTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗